Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 7/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | MPO | P05164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24406803 | 0.82 | MTNR1A (0.70) | HTR1DHTR1BHTR1AKDM4EMPO | |
| SCHEMBL13252962 | 0.82 | HTR1D (0.73) | HTR1DHTR1BHTR1AKDM4EMPO | |
| SCHEMBL7853204 | 0.82 | HTR1D (1.00) | HTR1DHTR1BHTR1AMPOCYP2D6 | |
| Hydrochloric Acid SCHEMBL7680692 | 0.81 | HTR1D (0.97) | HTR1DHTR1BHTR1AMPOCYP2D6 | |
| SCHEMBL4303662 | 0.80 | KDM4E (0.70) | HTR1DHTR1BHTR1AKDM4EMPO | |
| SCHEMBL21341623 | 0.80 | HTR1D (0.69) | HTR1DHTR1BHTR1ATRPV1 | |
| SCHEMBL13209526 | 0.79 | HTR1D (1.00) | HTR1DHTR1BHTR1AMPOCYP2D6 | |
| SCHEMBL19286645 | 0.79 | HTR1D (0.69) | HTR1DHTR1BHTR1AMPOHTR2A | |
| SCHEMBL10648384 | 0.79 | CHRNB2 (0.78) | HTR1DHTR1BHTR1AKDM4EMPO | |
| SCHEMBL2841739 | 0.79 | MPO (0.68) | HTR1DHTR1BHTR1AKDM4EMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551481-B2 | Molecular targets for addiction | THE JACKSON LABORATORY (US) | 2026-02-17 | — | — | US | disclosed |
| US-12391645-B2 | N-isopropyl tryptamines and method of making monoalkylated and dialkylated tryptamine analogs | CAAMTECH, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250197352-A1 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | CAAMTECH, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4525861-A2 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | Caamtech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023225679-A2 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | CAAMTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230057844-A1 | MOLECULAR TARGETS FOR ADDICTION | THE JACKSON LABORATORY (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11013717-B1 | Methods and compositions for treating cancer using SERCA pump inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200360364-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10683352-B1 | Methods for treating cancer using GRM8 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10457740-B1 | Methods and compositions for treating cancer using P2RX2 inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190233527-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CALCITONIN RECEPTOR ACTIVATORS | FLAGSHIP PIONEERING, INC. | 2019-08-01 | — | — | US | disclosed |
| WO-2018057576-A1 | DEUTERIUM-SUBSTITUTED PYRIDIN- AND PYRIMIDIN-2-YL-METHYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290992-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1D 10/4885HTR1B 7/4885HTR1A 3/4885 |
| US-12391645-B2 | N-isopropyl tryptamines and method of making monoalkylated and dialkylated tryptamine analogs | INMT, SLC6A4, HNMT | HTR1D 35/4885HTR1B 30/4885HTR1A 24/4885 |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | HTR1D 1651/4885HTR1B 428/4885HTR1A 573/4885 |
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1D 10/4885HTR1B 7/4885HTR1A 3/4885 |
| US-20200360364-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORS | CHRNA6, CHRNA1, CHRNG | HTR1D 1770/4885HTR1B 611/4885HTR1A 558/4885 |
| US-20250197352-A1 | N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS | INMT, SLC6A4, HNMT | HTR1D 35/4885HTR1B 30/4885HTR1A 24/4885 |
| US-10626105-B2 | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds | HTR2C, HTR5A, HTR1A | HTR1D 10/4885HTR1B 7/4885HTR1A 3/4885 |
| US-12551481-B2 | Molecular targets for addiction | HTR1D, HTR2A, HTR1A | HTR1D 1/4885HTR1B 8/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.